Evidence map›Paper›PMID 19055840›Full record

ArticleBMC bioinformatics2008

Global rank-invariant set normalization (GRSN) to reduce systematic distortions in microarray data.

Carl R Pelz, Molly Kulesz-Martin, Grover Bagby, Rosalie C Sears

Abstract read
In one paragraph

Article in BMC bioinformatics, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.

0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

35 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Predicting oncology drug-induced cardiotoxicity with donor-specific iPSC-CMs-a proof-of-concept study with doxorubicin.Toxicological sciences : an official journal of the Society of Toxicology · 2024
    Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Carl R PelzDepartment of Molecular and Medical Genetics, Oregon Health and Sciences University, Portland, OR 97239-3098, USA. pelzc@ohsu.edu
Molly Kulesz-Martin
Grover Bagby
Rosalie C Sears

Funding

OREGON CLINICAL AND TRANSLATIONAL SCIENCE INSTITUTEUL1RR024140 · NCRR · OREGON HEALTH & SCIENCE UNIVERSITY · PI ORWOLL, ERIC S. · 2006 to 2011
$61.1M
Understanding the origins of rapid recurrence of pancreatic cancer after resectionP30CA069533 · NCI · OREGON HEALTH & SCIENCE UNIVERSITY · PI Luiz Eduardo Bertassoni · 1997 to 2026
$60.5M
Xenograft CoreP01HL048546 · NHLBI · OREGON HEALTH & SCIENCE UNIVERSITY · PI ARMANT, MYRIAM · 1994 to 2020
$36.4M
TRAINING PROGRAM IN MOLECULAR HEMATOLOGYT32HL007781 · NHLBI · OREGON HEALTH & SCIENCE UNIVERSITY · PI BAGBY, GROVER CARLTON · 1993 to 2012
$5.1M
Training in the Molecular Basis of Skin/Mucosa PathobiologyT32CA106195 · NCI · OREGON HEALTH & SCIENCE UNIVERSITY · PI KULESZ-MARTIN, MOLLY F. · 2004 to 2018
$3.8M
Cellular Mechanisms Controlling Myc Protein StabilityR01CA100855 · NCI · OREGON HEALTH & SCIENCE UNIVERSITY · PI SEARS, ROSALIE C · 2003 to 2014
$3.6M
Microarray Program for NHLBI InvestigatorsR01HL072321 · NHLBI · OREGON HEALTH AND SCIENCE UNIVERSITY · PI BAGBY, GROVER CARLTON · 2002 to 2005
$2.9M
Mechanisms of SPAF and AS-FGF-2 in malignant conversionR01CA098893 · NCI · OREGON HEALTH AND SCIENCE UNIVERSITY · PI KULESZ-MARTIN, MOLLY F. · 2003 to 2005
$1.0M
Integration of Ras, Myc and E2F Signaling PathwaysK01CA086957 · NCI · OREGON HEALTH AND SCIENCE UNIVERSITY · PI SEARS, ROSALIE C · 2001 to 2005
$700k
NCI NIH HHS CA106195NCI NIH HHS CA98893NCI NIH HHS K01 CA086957NCI NIH HHS P30 CA069533NCI NIH HHS P30 CA69533NCI NIH HHS R01 CA098893NCI NIH HHS R01 CA100855NCI NIH HHS T32 CA106195NCRR NIH HHS UL1 RR024140NHLBI NIH HHS P01 HL048546NHLBI NIH HHS P01 HL48546NHLBI NIH HHS R01 HL072321NHLBI NIH HHS R01 HL72321NHLBI NIH HHS T32 HL007781
6 · The paper itself

Abstract

backgroundMicroarray technology has become very popular for globally evaluating gene expression in biological samples. However, non-linear variation associated with the technology can make data interpretation unreliable. Therefore, methods to correct this kind of technical variation are critical. Here we consider a method to reduce this type of variation applied after three common procedures for processing microarray data: MAS 5.0, RMA, and dChip.

resultsWe commonly observe intensity-dependent technical variation between samples in a single microarray experiment. This is most common when MAS 5.0 is used to process probe level data, but we also see this type of technical variation with RMA and dChip processed data. Datasets with unbalanced numbers of up and down regulated genes seem to be particularly susceptible to this type of intensity-dependent technical variation. Unbalanced gene regulation is common when studying cancer samples or genetically manipulated animal models and preservation of this biologically relevant information, while removing technical variation has not been well addressed in the literature. We propose a method based on using rank-invariant, endogenous transcripts as reference points for normalization (GRSN). While the use of rank-invariant transcripts has been described previously, we have added to this concept by the creation of a global rank-invariant set of transcripts used to generate a robust average reference that is used to normalize all samples within a dataset. The global rank-invariant set is selected in an iterative manner so as to preserve unbalanced gene expression. Moreover, our method works well as an overlay that can be applied to data already processed with other probe set summary methods. We demonstrate that this additional normalization step at the "probe set level" effectively corrects a specific type of technical variation that often distorts samples in datasets.

conclusionWe have developed a simple post-processing tool to help detect and correct non-linear technical variation in microarray data and demonstrate how it can reduce technical variation and improve the results of downstream statistical gene selection and pathway identification methods.

Indexed as

Gene Expression RegulationOligonucleotide Array Sequence AnalysisAnalysis of VarianceArtifactsComputational BiologyComputer SimulationDatabases, GeneticData Interpretation, StatisticalGene Expression ProfilingModels, GeneticReproducibility of ResultsSignal Transduction

Identifiers

PMID19055840
PMCPMC2644708

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.